# Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome

> **NCT04869930** · — · UNKNOWN · sponsor: **Nova Mentis Life Science Corp** · enrollment: 300 (estimated)

## Conditions studied

- Autism Spectrum Disorder
- Fra(X) Syndrome

## Interventions

- **OTHER:** specimen collection

## Key facts

- **NCT ID:** NCT04869930
- **Lead sponsor:** Nova Mentis Life Science Corp
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-11
- **Final completion:** 2023-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2021-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869930, "Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04869930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*